MLIVULT Trademark

Trademark Overview

On Wednesday, August 1, 2012, a trademark application was filed for MLIVULT with the United States Patent and Trademark Office. The USPTO has given the MLIVULT trademark a serial number of 85692930. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, April 4, 2016. This trademark is owned by Amgen Inc.. The MLIVULT trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for use in the treatment of oncological diseases and disorders, and complications associated therewith
mlivult

General Information

Serial Number85692930
Word MarkMLIVULT
Filing DateWednesday, August 1, 2012
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, April 4, 2016
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 9, 2013

Trademark Statements

Goods and ServicesPharmaceutical preparations for use in the treatment of oncological diseases and disorders, and complications associated therewith

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, August 10, 2012
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAmgen Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799
Party NameAmgen Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799

Trademark Events

Event DateEvent Description
Monday, April 4, 2016ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, April 4, 2016ABANDONMENT - NO USE STATEMENT FILED
Friday, August 14, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 13, 2015EXTENSION 4 GRANTED
Thursday, August 6, 2015EXTENSION 4 FILED
Thursday, August 6, 2015TEAS EXTENSION RECEIVED
Friday, January 23, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 22, 2015EXTENSION 3 GRANTED
Friday, January 16, 2015EXTENSION 3 FILED
Friday, January 16, 2015TEAS EXTENSION RECEIVED
Friday, August 22, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 21, 2014EXTENSION 2 GRANTED
Monday, July 28, 2014EXTENSION 2 FILED
Wednesday, August 20, 2014CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, July 28, 2014TEAS EXTENSION RECEIVED
Saturday, January 18, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 16, 2014EXTENSION 1 GRANTED
Thursday, January 16, 2014EXTENSION 1 FILED
Thursday, January 16, 2014TEAS EXTENSION RECEIVED
Tuesday, September 3, 2013NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 9, 2013OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 9, 2013PUBLISHED FOR OPPOSITION
Wednesday, June 19, 2013NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, June 6, 2013LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, June 6, 2013ASSIGNED TO LIE
Monday, May 20, 2013APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, May 20, 2013EXAMINER'S AMENDMENT ENTERED
Monday, May 20, 2013NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, May 20, 2013EXAMINERS AMENDMENT E-MAILED
Monday, May 20, 2013EXAMINERS AMENDMENT -WRITTEN
Tuesday, December 4, 2012NOTIFICATION OF PRIORITY ACTION E-MAILED
Tuesday, December 4, 2012PRIORITY ACTION E-MAILED
Tuesday, December 4, 2012PRIORITY ACTION WRITTEN
Wednesday, November 28, 2012ASSIGNED TO EXAMINER
Friday, August 10, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, August 4, 2012NEW APPLICATION ENTERED IN TRAM

Related Keywords

mlivult complications associated therewith disorders diseases preparations treatment oncological pharmaceutical